News

Evotec has formed a partnership with Charité – Universitätsmedizin Berlin in Germany to build a database of all sorts of molecular information from people with ANCA-associated vasculitis (AAV). Molecular profiles, a kind of fingerprint of AAV, may help scientists better understand the autoimmune disease and pave the way…

Factor XII (FXII), a protein involved in blood clotting, is found at significantly higher levels in the blood of people with active ANCA-associated vasculitis (AAV) relative to those in clinical remission, or whose symptoms have eased or disappeared. That’s according to a study in China that also found that…

ANCA-associated vasculitis (AAV) with kidney involvement is the most common cause of kidney disease among elderly people, but most older patients appear to benefit from appropriate therapy as well as younger AAV patients with kidney damage. That’s according to a study in Germany that found no significant differences in…

A first patient has been dosed in a Phase 2 clinical trial testing lixudebart, Alentis Therapeutics‘ investigational antibody therapy, in ANCA-associated vasculitis (AAV) patients with rapidly progressing glomerulonephritis (RPGN), a serious kidney disease. The study, RENAL-F02 (NCT06047171), currently is recruiting up to 60 adults with AAV…

ANCA-associated vasculitis (AAV) patients who are older and taking pulses of methylprednisolone as an induction therapy are more likely to have a greater drop in protective IgG antibody levels during maintenance therapy with rituximab, raising a significant risk of severe infections, a study from France reports. A lower…

Common variants in genes that encode proteins of the alternative complement pathway, a part of the immune system, may raise the risk of ANCA-associated vasculitis (AAV) and severe disease-related kidney damage, a study shows. Researchers also found a link between worse disease outcomes and AAV…

In a Phase 3 trial of Tavneos (avacopan) in people with ANCA-associated vasculitis (AAV), the therapy’s effectiveness in the subgroup of patients on standard induction treatment with rituximab was similar to that of the overall study population. Reasonable safety also was seen, and sustained one-year remission was higher…

An 18-month fixed-schedule maintenance regimen of rituximab is better at keeping ANCA-associated vasculitis (AAV) in remission for up to seven years than azathioprine or a rituximab regimen tailored to an individual, according to pooled data from the Phase 3 MAINRITSAN program. Doubling the length of this fixed-schedule regimen did…

A Phase 2 clinical trial testing Q32 Bio’s ADX-097 in people with ANCA-associated vasculitis (AAV) will be the result of a recently announced merger between the company and Homology Medicines. While further details on the trial were not disclosed, results are expected in the second half of…

About one-quarter of adults with ANCA-associated vasculitis (AAV) in which their lungs are affected have small airway disease (SAD), which targets the tiny airways in the lungs, according to a study in China. Younger age, the presence of clumps of inflammatory cells called granulomas in the lungs, and other…